Opus Genetics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Opus Genetics, Inc. (IRD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Opus Genetics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.41M, a 57.03% increase year-over-year.
- Opus Genetics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.46M, a 60.35% increase year-over-year.
- Opus Genetics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $816.00K, a 5.15% increase year-over-year.
- Opus Genetics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $896.00K, a 11.17% increase year-over-year.
- Opus Genetics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $3.40M, a 1.10% increase from fiscal 2024.
- Opus Genetics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $3.36M, a 4.22% decline from fiscal 2023.
- Opus Genetics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.51M, a 94.24% increase from fiscal 2022.
- Opus Genetics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.81M, a 5.59% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.41M 10-Q · filed 2026-08-06 | $2.87M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $1.46M 10-Q · filed 2026-08-06 | |||||
| 2025-12-31 | $3.40M 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | $816.00K 10-Q · filed 2025-11-12 | $1.71M derived: sum of 2 quarters · filed 2026-08-06 | $2.63M derived: sum of 3 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $896.00K 10-Q · filed 2026-08-06 | $1.81M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $913.00K 10-Q · filed 2026-08-06 | |||||
| 2024-12-31 | $3.36M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | $776.00K 10-Q · filed 2025-11-12 | $1.58M derived: sum of 2 quarters · filed 2025-11-12 | $2.57M derived: sum of 3 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $806.00K 10-Q · filed 2025-11-12 | $1.79M derived: sum of 2 quarters · filed 2025-11-12 | ||||
| 2024-03-31 | $985.00K 10-Q · filed 2025-11-12 | |||||
| 2023-12-31 | $3.51M 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | $573.00K 10-Q · filed 2024-11-12 | $2.00M derived: sum of 2 quarters · filed 2024-11-12 | $2.80M derived: sum of 3 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $1.42M 10-Q · filed 2024-11-12 | $2.23M derived: sum of 2 quarters · filed 2024-11-12 | ||||
| 2023-03-31 | $804.00K 10-Q · filed 2024-11-12 | |||||
| 2022-12-31 | $1.81M 10-K · filed 2024-03-08 | |||||
| 2022-09-30 | $493.00K 10-Q · filed 2023-11-13 | $938.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.38M derived: sum of 3 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $445.00K 10-Q · filed 2023-11-13 | $890.00K derived: sum of 2 quarters · filed 2023-11-13 | ||||
| 2022-03-31 | $445.00K 10-Q · filed 2023-11-13 | |||||
| 2021-12-31 | $1.91M 10-K · filed 2023-03-30 | |||||
| 2021-09-30 | $478.00K 10-Q · filed 2022-11-04 | $941.00K derived: sum of 2 quarters · filed 2022-11-04 | $1.44M derived: sum of 3 quarters · filed 2022-11-04 | $2.74M derived: sum of 4 quarters · filed 2022-11-04 | ||
| 2021-06-30 | $463.00K 10-Q · filed 2022-11-04 | $957.00K derived: sum of 2 quarters · filed 2022-11-04 | $2.26M derived: sum of 3 quarters · filed 2022-11-04 | $2.88M derived: sum of 4 quarters · filed 2022-11-04 | ||
| 2021-03-31 | $494.00K 10-Q · filed 2022-11-04 | $1.80M derived: sum of 2 quarters · filed 2022-11-04 | $2.41M derived: sum of 3 quarters · filed 2022-11-04 | $2.73M derived: sum of 4 quarters · filed 2022-11-04 | ||
| 2020-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $1.92M derived: sum of 2 quarters · filed 2022-03-24 | $2.24M derived: sum of 3 quarters · filed 2022-03-24 | $1.51M 10-K · filed 2022-03-24 | ||
| 2020-09-30 | $616.00K 10-Q · filed 2021-11-12 | $56.84K 10-Q · filed 2020-10-29 | $932.00K derived: sum of 2 quarters · filed 2021-11-12 | $202.21K 10-Q · filed 2020-10-29 | $921.65K derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $316.00K 10-Q · filed 2021-11-12 | $69.07K 10-Q · filed 2020-08-14 | $145.37K 10-Q · filed 2020-08-14 | $305.65K derived: sum of 3 quarters · filed 2021-11-12 | $396.35K derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-03-31 | $61.00K 10-Q · filed 2021-11-12 | $76.30K 10-Q · filed 2020-05-07 | -$10.35K derived: sum of 2 quarters · filed 2021-11-12 | $80.35K derived: sum of 3 quarters · filed 2021-11-12 | $208.00K derived: sum of 4 quarters · filed 2021-11-12 | |
| 2019-12-31 | -$71.35K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $19.35K derived: sum of 2 quarters · filed 2021-03-11 | $147.00K derived: sum of 3 quarters · filed 2021-03-11 | $308.00K 10-K · filed 2021-03-11 | $456.75K 10-K · filed 2020-02-21 | |
| 2019-09-30 | $90.69K 10-Q · filed 2020-10-29 | $218.35K derived: sum of 2 quarters · filed 2020-10-29 | $379.35K 10-Q · filed 2020-10-29 | $762.47K derived: sum of 4 quarters · filed 2020-10-29 | ||
| 2019-06-30 | $127.65K 10-Q · filed 2020-08-14 | $288.65K 10-Q · filed 2020-08-14 | $671.78K derived: sum of 3 quarters · filed 2020-08-14 | $953.26K derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | $161.00K 10-Q · filed 2020-05-07 | $544.13K derived: sum of 2 quarters · filed 2020-05-07 | $825.61K derived: sum of 3 quarters · filed 2020-05-07 | $1.09M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $383.13K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $664.61K derived: sum of 2 quarters · filed 2020-02-21 | $931.76K derived: sum of 3 quarters · filed 2020-02-21 | $1.23M 10-K · filed 2020-02-21 | ||
| 2018-09-30 | $281.48K 10-Q · filed 2019-11-06 | $548.63K derived: sum of 2 quarters · filed 2019-11-06 | $845.21K 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $267.15K 10-Q · filed 2019-08-07 | $563.73K 10-Q · filed 2019-08-07 | ||||
| 2018-03-31 | $296.58K 10-Q · filed 2019-05-10 | |||||
| 2017-12-31 | $1.04M 10-K · filed 2019-03-07 | |||||
| 2016-12-31 | $1.41M 10-K · filed 2018-03-09 | |||||
| 2015-12-31 | $1.04M 10-K · filed 2018-03-09 | |||||
| 2014-12-31 | $608.79K 10-K · filed 2017-02-24 | |||||
| 2013-12-31 | $565.43K 10-K · filed 2016-03-14 | |||||
| 2012-12-31 | $230.99K 10-K · filed 2014-03-21 | |||||
| 2011-12-31 | $638.61K 10-K · filed 2014-03-21 | |||||
| 2010-12-31 | $584.66K 10-K · filed 2014-03-21 | |||||
| 2009-12-31 | $497.53K 10-K · filed 2014-03-21 | |||||
| 2008-12-31 | $484.68K 10-K · filed 2014-03-21 | |||||
| 2007-12-31 | $1.12M 10-K · filed 2014-03-21 | |||||
| 2006-12-31 | $1.03M 10-K · filed 2014-03-21 | |||||
| 2005-12-31 | $436.75K 10-K · filed 2014-03-21 | |||||
| 2004-12-31 | $230.77K 10-K · filed 2014-03-21 | |||||
| 2003-12-31 | $538.07K 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |